Dr. Cibere has received honoraria (less than $10,000 each) from Eli Lilly and Pfizer.
Cost-Utility Analysis of a Multidisciplinary Strategy to Manage Osteoarthritis of the Knee: Economic Evaluation of a Cluster Randomized Controlled Trial Study†
Version of Record online: 27 MAY 2014
Copyright © 2014 by the American College of Rheumatology
Arthritis Care & Research
Volume 66, Issue 6, pages 810–816, June 2014
How to Cite
Marra, C. A., Grubisic, M., Cibere, J., Grindrod, K. A., Woolcott, J. C., Gastonguay, L. and Esdaile, J. M. (2014), Cost-Utility Analysis of a Multidisciplinary Strategy to Manage Osteoarthritis of the Knee: Economic Evaluation of a Cluster Randomized Controlled Trial Study. Arthritis Care Res, 66: 810–816. doi: 10.1002/acr.22232
ClinicalTrials.gov identifier: NCT00391859.
- Issue online: 27 MAY 2014
- Version of Record online: 27 MAY 2014
- Accepted manuscript online: 18 NOV 2013 01:36PM EST
- Manuscript Accepted: 5 NOV 2013
- Manuscript Received: 14 JAN 2013
To determine if a pharmacist-initiated multidisciplinary strategy provides value for money compared to usual care in participants with previously undiagnosed knee osteoarthritis.
Pharmacies were randomly allocated to provide either 1) usual care and a pamphlet or 2) intervention care, which consisted of education, pain medication management by a pharmacist, physiotherapy-guided exercise, and communication with the primary care physician. Costs and quality-adjusted life-years (QALYs) were determined for patients assigned to each treatment and incremental cost-effectiveness ratios (ICERs) were determined.
From the Ministry of Health perspective, the average patient in the intervention group generated slightly higher costs compared with usual care. Similar findings were obtained when using the societal perspective. The intervention resulted in ICERs of $232 (95% confidence interval [95% CI] −1,530, 2,154) per QALY gained from the Ministry of Health perspective and $14,395 (95% CI 7,826, 23,132) per QALY gained from the societal perspective, compared with usual care.
A pharmacist-initiated, multidisciplinary program was good value for money from both the societal and Ministry of Health perspectives.